pmc-enju-pas Home  

PMC:2664230 / 2711-3055 JSONTXT 18 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1699 0-11 RB denotes Furthermore
T1700 11-12 -COMMA- denotes ,
T1701 13-18 NN denotes TNF-α
T1702 19-28 NN denotes synthesis
T1703 29-32 MD denotes can
T1704 33-35 VB denotes be
T1705 36-46 VB denotes attenuated
T1706 47-49 IN denotes in
T1707 50-56 JJ denotes immune
T1708 57-62 NN denotes cells
T1709 63-70 VB denotes exposed
T1710 71-73 TO denotes to
T1711 74-91 NN denotes phosphodiesterase
T1712 92-93 -LRB- denotes (
T1713 93-96 NN denotes PDE
T1714 96-97 -RRB- denotes )
T1715 98-108 NN denotes inhibition
T1716 109-114 IN denotes after
T1717 115-124 NN denotes challenge
T1718 125-127 IN denotes by
T1719 128-129 DT denotes a
T1720 130-137 NN denotes variety
T1721 138-140 IN denotes of
T1722 141-157 JJ denotes pro-inflammatory
T1723 158-170 NN denotes stimulants.4
T1724 171-174 DT denotes The
T1725 175-184 NN denotes signaling
T1726 185-195 NN denotes mechanisms
T1727 196-204 VB denotes affected
T1728 205-207 IN denotes by
T1729 208-211 NN denotes PDE
T1730 212-222 NN denotes inhibition
T1731 222-223 -COMMA- denotes ,
T1732 224-229 WDT denotes which
T1733 230-240 RB denotes ultimately
T1734 241-245 VB denotes lead
T1735 246-248 TO denotes to
T1736 249-252 DT denotes the
T1737 253-267 NN denotes downregulation
T1738 268-270 IN denotes of
T1739 271-276 NN denotes TNF-α
T1740 277-287 NN denotes production
T1741 287-288 -COMMA- denotes ,
T1742 289-293 VB denotes have
T1743 294-297 RB denotes not
T1744 298-302 VB denotes been
T1745 303-307 RB denotes well
T1746 308-321 VB denotes characterized
T1747 322-324 IN denotes in
T1748 325-337 JJ denotes inflammatory
T1749 338-343 NN denotes cells
R1387 T1702 T1701 arg1Of synthesis,TNF-α
R1388 T1702 T1703 arg1Of synthesis,can
R1389 T1702 T1704 arg1Of synthesis,be
R1390 T1702 T1705 arg2Of synthesis,attenuated
R1391 T1705 T1703 arg2Of attenuated,can
R1392 T1705 T1704 arg2Of attenuated,be
R1393 T1705 T1706 arg1Of attenuated,in
R1394 T1705 T1716 arg1Of attenuated,after
R1395 T1708 T1706 arg2Of cells,in
R1396 T1708 T1707 arg1Of cells,immune
R1397 T1708 T1709 arg2Of cells,exposed
R1398 T1709 T1710 arg1Of exposed,to
R1399 T1711 T1712 arg1Of phosphodiesterase,(
R1400 T1713 T1712 arg2Of PDE,(
R1401 T1714 T1712 arg3Of ),(
R1402 T1715 T1710 arg2Of inhibition,to
R1403 T1715 T1711 arg1Of inhibition,phosphodiesterase
R1404 T1717 T1716 arg2Of challenge,after
R1405 T1717 T1718 arg1Of challenge,by
R1406 T1720 T1718 arg2Of variety,by
R1407 T1720 T1719 arg1Of variety,a
R1408 T1720 T1721 arg1Of variety,of
R1409 T1723 T1721 arg2Of stimulants.4,of
R1410 T1723 T1722 arg1Of stimulants.4,pro-inflammatory
R1411 T1726 T1724 arg1Of mechanisms,The
R1412 T1726 T1725 arg1Of mechanisms,signaling
R1413 T1726 T1727 arg2Of mechanisms,affected
R1414 T1726 T1731 arg1Of mechanisms,","
R1415 T1726 T1732 arg1Of mechanisms,which
R1416 T1726 T1734 arg1Of mechanisms,lead
R1417 T1726 T1742 arg1Of mechanisms,have
R1418 T1726 T1744 arg1Of mechanisms,been
R1419 T1726 T1746 arg2Of mechanisms,characterized
R1420 T1730 T1727 arg1Of inhibition,affected
R1421 T1730 T1728 arg2Of inhibition,by
R1422 T1730 T1729 arg1Of inhibition,PDE
R1423 T1734 T1733 arg1Of lead,ultimately
R1424 T1734 T1735 arg1Of lead,to
R1425 T1737 T1735 arg2Of downregulation,to
R1426 T1737 T1736 arg1Of downregulation,the
R1427 T1737 T1738 arg1Of downregulation,of
R1428 T1740 T1738 arg2Of production,of
R1429 T1740 T1739 arg1Of production,TNF-α
R1430 T1746 T1699 arg1Of characterized,Furthermore
R1431 T1746 T1700 arg1Of characterized,","
R1432 T1746 T1703 modOf characterized,can
R1433 T1746 T1741 arg1Of characterized,","
R1434 T1746 T1742 arg2Of characterized,have
R1435 T1746 T1743 arg1Of characterized,not
R1436 T1746 T1744 arg2Of characterized,been
R1437 T1746 T1745 arg1Of characterized,well
R1438 T1746 T1747 arg1Of characterized,in
R1439 T1749 T1747 arg2Of cells,in
R1440 T1749 T1748 arg1Of cells,inflammatory